828 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B Downtrend
Article Searches
Company News For May 22, 2019 http://www.zacks.com/stock/news/417942/company-news-for-may-22-2019?cid=CS-ZC--417942 May 22, 2019 - Companies In The News Are: KSS,AZO,HD,MRK
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/416744/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-416744 May 20, 2019 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
AbbVie's Brain Cancer Candidate Fails in Phase III Study http://www.zacks.com/stock/news/416716/abbvies-brain-cancer-candidate-fails-in-phase-iii-study?cid=CS-ZC-FT-416716 May 20, 2019 - AbbVie's (ABBV) phase III study on Depatux-M, an investigational candidate for newly diagnosed glioblastoma, fails to show survival benefit in patients receiving Depatux-M.
Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs http://www.zacks.com/stock/news/415516/pharma-stock-roundup-fda-okays-line-extensions-of-lly-pfe-abbv-cancer-drugs?cid=CS-ZC-FT-415516 May 17, 2019 - FDA grants approval for line extensions of Lilly (LLY), Pfizer (PFE) and Roche (RHHBY)/AbbVie's (ABBV) cancer drugs
ImmunoGen Plunges as FDA Recommends New Study for Lead Drug http://www.zacks.com/stock/news/415333/immunogen-plunges-as-fda-recommends-new-study-for-lead-drug?cid=CS-ZC-FT-415333 May 16, 2019 - FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.
Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer http://www.zacks.com/stock/news/414385/pfizers-bavencio%2Binlyta-combo-gets-fda-nod-for-kidney-cancer?cid=CS-ZC-FT-414385 May 15, 2019 - Pfizer (PFE)/Merck KGaA's label expansion application for Bavencio as a treatment for advanced kidney cancer in combination with Inlyta gets approval in the United States.
Lilly's Cyramza Gets FDA Nod for Second-Line Liver Cancer http://www.zacks.com/stock/news/413860/lillys-cyramza-gets-fda-nod-for-second-line-liver-cancer?cid=CS-ZC-FT-413860 May 14, 2019 - Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
What's in Store for Affimed (AFMD) This Earnings Season? http://www.zacks.com/stock/news/413239/whats-in-store-for-affimed-afmd-this-earnings-season?cid=CS-ZC-FT-413239 May 13, 2019 - Affimed (AFMD) is likely to provide update on the progress of its pipeline candidates when its reports first-quarter results.
Endo (ENDP) Q1 Earnings & Revenues Beat Estimates http://www.zacks.com/stock/news/412848/endo-endp-q1-earnings-revenues-beat-estimates?cid=CS-ZC-FT-412848 May 10, 2019 - Endo's (ENDP) earnings and revenues top expectations in the first quarter of 2019.
Pharma Stock Roundup: AGN, NVO Report Q1 Earnings, NVS to Buy Takeda's Eye Drug http://www.zacks.com/stock/news/412433/pharma-stock-roundup-agn-nvo-report-q1-earnings-nvs-to-buy-takedas-eye-drug?cid=CS-ZC-FT-412433 May 10, 2019 - Allergan (AGN) and Novo Nordisk (NVO) announce Q1 results. Novartis buys rights to Takeda's dry eye disease drug, Xiidra.

Pages: 123456...83

Page 1>